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Abstract Encapsulating peritoneal sclerosis (EPS)
is an infrequent but serious complication of perito-
neal dialysis (PD). The pathogenesis is unknown but
speculation is ongoing. The current management of
EPS focuses on prevention and treatment of the
inﬂammatory and ﬁbrotic changes at the level of the
peritoneal membrane with immunosuppressive and
antiﬁbrotic agents, respectively. This article reviews
the currently available human and animal data on
potential agents to prevent and/or treat EPS. We
propose a strategy for early diagnose EPS in an
attempt to avoid the development of the full-blown
and potentially life-threatening clinical syndrome of
EPS. Future research should focus on studying
potential prophylactic and therapeutic agents in
humans in large, multicenter, randomized trials but
also on early detection of EPS in the inﬂammatory
phase by means of biomarkers and the establishment
of a composite EPS score.
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Introduction
Encapsulating peritoneal sclerosis (EPS) is a rare but
potentially life-threatening complication of peritoneal
dialysis (PD). After a period of 1–3 years on PD, all
patients develop simple peritoneal sclerosis, but only
few of them will progress to the syndrome of EPS
that potentially consists of ultraﬁltration failure with
a high transport status, intermittent small-bowel
obstruction and/or weight loss [1]. On abdominal
imaging with computed tomography (CT), peritoneal
thickening, adhesions of bowel loops, signs of
obstruction and ﬂuid collections are usually present
[2]. The high morbidity and mortality of EPS is
attributed to malnutrition and sepsis. The prevalence
of EPS varies between 0.5 and 7.3% but may increase
to as high as 15.2% in patients on PD for more than
15 years [3]. EPS frequently occurs after cessation of
PD, perhaps because cessation of lavage may lead to
accumulation of ﬁbrin, cytokines and growth factors,
leading to inﬂammation and ﬁbrosis. EPS is also
common in the post-transplant period [4], possibly
because of the current tendency to decrease the dose
of prednisone in transplantation together with the use
of pro-ﬁbrotic calcineurin inhibitors (CNI). The
etiology of EPS is unclear but the speculation is a
‘two-hit’ hypothesis. The use of bio-incompatible
solutions (containing glucose, glucose-degradation
products and lactate in an acid solution) and exposure
to toxins such as plasticizers and chlorhexidine leads
to loss of normal mesothelial cell morphology,
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(epithelial-to-mesenchymal transition) and also to
neovascularization [5]. This is considered to be the
‘ﬁrst hit’ in the development of EPS. The ‘second hit’
is often discontinuation of PD, an episode of severe
PD peritonitis or any other peritoneal trauma such as
abdominal surgery. A genetic predisposition to this
second hit might put some patients at higher risk for
developing EPS. Enhanced production of transform-
ing growth factor beta (TGF-beta) and vascular
endothelial growth factor (VEGF) plays a central
role in ﬁbrosis and neoangiogenesis, the two basic
mechanisms in the pathogenesis of EPS [6].
The treatment of EPS is still controversial but is
most often proposed to be a combination of cessation
of PD as well as the use of immunosuppressive and
antiﬁbrotic agents together with nutritional support.
Surgical intervention with enterolysis and decortica-
tion is common practice in Japan but less frequent in
other parts of the world [7].
This review focuses on the reported use and
beneﬁts of immunosuppressive and antiﬁbrotic agents
in EPS. We reviewed through an extensive PubMed
search the currently available human as well as
animal data for the prevention and treatment of EPS.
Human data on medical treatment for EPS
Tamoxifen
Tamoxifen is a selective estrogen receptor modulator
(SERM) that inhibits the production of TGF-beta by
ﬁbroblasts. It has been used in the past in several
ﬁbrosing syndromes such as retroperitoneal ﬁbrosis
and ﬁbrosing mediastinitis [8].
Guest recently summarized the available clinical
data for the usage of tamoxifen in EPS [9]. Between
1992 and 2007, 14 different groups have reported on
their experience with tamoxifen therapy for EPS. The
number of patients varied between 1 and 14 in each
group. In total, 36 patients were studied. Twenty-one
patients received tamoxifen as sole therapy, 8 patients
were also treated with steroids (of which 1 patient
also received azathioprine), 2 patients received
rapamycin together with tamoxifen and 5 patients
underwent surgery in conjunction with tamoxifen
treatment. Doses of tamoxifen varied between 10 and
80 mg per day. In 2 patients, the outcome was
reported as ‘resolved’, 20 patients ‘improved’, 14
patients remained ‘stable’, 4 patients died and in 1
patient the outcome was not reported.
Del Peso extended the use of tamoxifen to patients
with pre-EPS changes in a non-randomized study
[10]. A total of 23 PD patients with peritoneal
sclerosis, who had ultraﬁltration failure and a high
transport status but without the typical CT ﬁndings
for EPS, were studied for a period of 47 (tamoxifen
group) and 29 (control group) months. None of the 9
patients in the ‘tamoxifen as prophylaxis’ arm did
progress to full-blown EPS. However, 4 of the 14
patients in the control group who did not receive
tamoxifen developed EPS and died. Tamoxifen dose
in this study was 40 mg per day; steroids were not
used.
Tamoxifen is generally well tolerated. Potential
side effects include hot ﬂushes, nausea, fatigue,
endometrial carcinoma and deep venous thrombosis.
Evidently, randomized, controlled trials are necessary
to assess the efﬁcacy of tamoxifen for prophylactic
and therapeutic management of EPS. Particulary
interesting is indeed the idea to start treating EPS in
the early stages with tamoxifen. This could be applied
to patients on long-standing PD, who develop ultra-
ﬁltration failure with a high transport status but who
do not have the typical imaging changes as expected
in EPS.
Glucocorticoids
In1997,Moriandcolleaguesreportedfortheﬁrst time
on the successful use of steroids alone in one patient
with EPS [11]. In 1999, Martins and colleagues also
reported on one patient who was successfully treated
forEPSwith prednisone100 mgperday,taperedtobe
stopped over 4.5 months [12]. The patient responded
excellentlywithrecoveryoflostweight,normalization
of serum albumin and disappearance of the ‘cocoon-
ing’ on CT of his abdomen. This patient also received
azathioprine 50 mg per day for 2.5 months. In 2001,
Kuriyama and Tomonori reported on their experience
in the treatment of EPS before and after 1997, the year
whereinthedecisionwasmadetotreatallEPSpatients
with prednisolone 0.5 mg/kg per day [13]. All 6
patientsbefore1997diedasaconsequenceofEPS,and
all 5 patients treated after 1997 were alive and doing
well. The use of steroids for the treatment of EPS was
subsequentlyconﬁrmedasasuccessfulstrategyinarat
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induced in 20 rats by an acid dialysis solution.
Glucocorticoid treatment prevented the progression
of peritoneal ﬁbrosis and adhesion of peritoneum.
Dejagere and colleagues presented a patient who
developed EPS after renal transplantation and who
was successfully treated with high doses of corticoste-
roids[15].Asubsequentrelapse,mostlikelyduetofast
tapering of the steroid dose, responded well to an
increase in the steroid dose.
The pharmacological mode of corticosteroid
action on EPS is still unknown. However, the
speculation is that it may be via both the anti-
inﬂammatory effect and the immunosuppressive
effect of it. Matsuo et al. [16] recently showed, in
a rat model, that prednisolone inhibits the glucose-
mediated induction of monocyte chemoattractant
protein-1 (MCP-1), which is important in recruiting
monocytes and promoting ﬁbrosis in peritoneal
sclerosis. Glucose is supposed to upregulate MCP-
1 through hyperosmolarity by activating protein
kinase C (PKC) and its downstream NF-kappa B
signaling.
Azathioprine
Azathioprine (AZA) has shown advantages in anec-
dotal case reports in humans. Wong and colleagues
reported on two patients with EPS who were treated
with AZA [17]. The ﬁrst patient was started on AZA
125 mg per day (1.5 mg/kg/day) and prednisolone
30 mg per day. Gastro-intestinal symptoms improved
quickly, and his body weight and serum albumin
normalized, and subsequently, AZA was gradually
tapered to 75 mg per day and prednisolone to 20 mg
per day. The second patient reported by Wong et al.
made a full recovery within 4 weeks of starting the
dual immunosuppressive treatment. Junor et al. [18]
suggested the beneﬁcial role of AZA in EPS from the
ﬁnding that ﬁve PD patients who developed EPS after
renal transplant had a prolonged survival with or
without functioning graft, when compared to twelve
PD patients who were not on immunosuppression and
died within a year after developing EPS. He attrib-
uted the benign EPS course of the renal transplant
patients to AZA being part of the immunosuppressive
regime.
They hypothesized that immunosuppression sup-
presses the uncontrollable ﬁbrogenesis and the
inﬂammatory inﬁltrate of the peritoneal membrane
that causes EPS.
A recent animal study with 52 non-uremic rats
with EPS, however, could not show any beneﬁt of
AZA for the treatment of EPS [19]. In the steroid
group on the other hand, there was a lower ﬁbrosis
score and less peritoneal thickness when compared to
the control animals.
Mycophenolate mofetil
Mycophenolate mofetil (MMF) has been shown to be
efﬁcacious for EPS treatment in three patients
reported by Lafrance et al. [20]. The ﬁrst patient
received colchicine 0.6 mg per day, prednisone
50 mg per day for 2 weeks with progressive tapering
to 25 mg per day and MMF 500 mg twice a day. Her
general condition improved dramatically together
with resolution of the abdominal pain syndrome and
normalization of the serum albumin. A repeat CT
abdomen showed less thickening of the peritoneal
membrane and normal bowel loops. This patient
underwent living donor kidney transplantation 1 year
later. The second patient was treated with prednisone
25 mg per day tapered over 2 months to 15 mg per
day together with MMF 500 mg twice a day.
Abdominal symptoms and fever resolved rapidly,
and both prednisone and MMF were stopped after
6 months of treatment. The third patient was treated
with prednisone 50 mg per day and MMF 500 mg
twice per day with rapid clinical and radiological
improvement. Both prednisone and MMF were held
2 months after initiation of the treatment because of
disseminated herpes zoster.
All three patients showed signiﬁcant improvement
within a month after MMF was started in combina-
tion with steroids, and all three patients were still
alive more than 2 years after EPS was diagnosed.
None of them experienced a relapse. We question,
however, whether it was the MMF or the concomitant
use of steroids that had the greatest impact on the
EPS course. No other data on the use of MMF in the
treatment of EPS are available.
Conclusion on human data
Human data suggest that tamoxifen and steroids
might be useful in the prevention and/or treatment of
EPS. Data on AZA and MMF are scarce and weak.
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higher risk to develop EPS, although being treated
with steroids and AZA or MMF, lies, as stated before,
in the use of lower steroid dose and in the use of CNI
in current immunosuppressive regimes.
Experimental data on medical treatment for EPS
Rosiglitazone
Rosiglitazone is a peroxisome proliferator-activated
receptor (PPAR) agonist. PPARs are the major
regulators of key metabolic pathways of various
inﬂammatory responses in ﬁbrosing processes in
most tissues. PPAR gamma receptors are expressed
in mesothelial cells [21]. PPAR gamma plays a
signiﬁcant role in cell differentiation as well as in
anti-inﬂammatory and antiangiogenic responses.
They might therefore have a potential role in
peritoneal defense. Bozkurt et al. [22] investigated
the effect of rosiglitazone on progression and regres-
sion of EPS in 53 non-uremic rats with EPS. They
found that rosiglitazone was more effective than
peritoneal resting (leaving peritoneal cavity empty
for 3 weeks till time of analysis after intraperitoneal
chlorhexidine administration for initial 3 weeks) for
almost all of the functional and structural peritoneal
parameters, including an improvement in dialysate
over plasma urea concentration (D/P urea) and
ultraﬁltration (UF) capacity and a decrease in
inﬂammatory cell count and neoangiogenesis. These
authors suggest that rosiglitazone may have a role in
the prevention of EPS by inhibiting inﬂammation and
neovascularization, especially in diabetes.
N-acetylcysteine
The well-known antioxidant N-acteylcysteine (NAC)
is a capable reactive oxygen species (ROS) scaven-
ger. Generation of ROS, as for instance by the
presence of bio-incompatible PD solutions, might be
responsible for progressive peritoneal membrane
dysfunction and ﬁbrosis. NAC also inhibits VEGF
and decreases the activity of angiotensin II and TGF-
beta1 in human peritoneal mesothelial cells [23].
The group of Bozkurt studied 39 non-uremic rats
to assess the prophylactic and therapeutic effect of
NAC in EPS [24]. NAC signiﬁcantly improved
peritoneal UF failure and neovascularization when
compared with peritoneal resting. Surprisingly, there
was no protective effect of NAC on ﬁbrosis. How-
ever, the authors considered the decreased inﬂamma-
tion and vascularity to be promising for peritoneal
membrane protection.
Colchicine
Colchicine is a well-known anti-inﬂammatory and
antiﬁbrotic agent. It also decreases the TGF-beta1
mRNA expression in idiopathic pulmonary ﬁbrosis
[25].
In a study of 48 non-uremic rats with EPS,
colchicine resulted in signiﬁcantly better UF volume
when compared to the peritoneal resting group [26].
In the colchicine-regression group (intraperitoneal
chlorhexidine for 3 weeks followed by colchicine in
drinking water for 3 weeks), colchicine signiﬁcantly
improved peritoneal thickness and neovascularization
compared to the resting group. In the colchicine-
progression group (in which intraperitoneal chlorh-
exidine and oral colchicine were administered
together during 3 weeks), there was a more pro-
nounced effect of colchicine on ﬁbrosis compared to
the regression model. This ﬁnding might be compat-
ible with the suggestion of an early inﬂammatory
phase in the course of EPS and possibly conﬁrms the
need for early intervention before irreversible
changes take place. In conclusion, colchicine was
shown to have protective effects on membrane
integrity via decreased inﬂammation, cell inﬁltration
and vascularity.
Renin–angiotensin system inhibition
Angiotensin II promotes ﬁbrosis and inﬂammation in
various tissues via the enhanced gene expression of
TGF-beta1, VEGF, epidermal growth factor (EGF),
plasminogen activator inhibitor and pro-inﬂammatory
cytokines. It plays an important role in ﬁbrotic
disease processes such as diabetic nephropathy,
cardiac remodeling and hypertensive vasculopathy.
The role of angiotensin II in peritoneal ﬁbrosis has
also been well described [27].
Sawada et al. [28] studied the antiﬁbrotic effects of
quinapril, an ACE inhibitor, on mice with EPS.
Macroscopic examination revealed that ﬁbrotic
changes in the parietal peritoneum were statistically
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EPS was induced with intraperitoneal chlorhexidine
and ethanol compared to the animals in which
intraperitoneal chlorhexidine and ethanol were
administered together with oral quinapril. Histolog-
ical examination demonstrated that peritoneal thick-
ening was clearly improved in the quinapril group.
Kyuden et al. [29] showed, in a cultured human
peritoneal mesothelial cell model, that perindopril
and candesartan attenuated the increased production
of TGF-beta1 and that they reduced cell proliferation
caused by exposure to high glucose. These effects
were greater with the combination of both drugs.
Nakamoto et al. [30] studied the effects of the
orally administered angiotensin receptor blocker
olmesartan versus the calcium channel blocker
amlodipine on peritoneal ﬁbrosis in 40 hypertensive
rats in which EPS was induced by a glucose-
containing acid dialysis solution. Treatment with
olmesartan prevented the progression of peritoneal
ﬁbrosis and adhesions, on which amlodipine did not
have an impact.
In another non-uremic EPS rat model, the advan-
tages of renin–angiotensin system (RAS) blockade in
regression of EPS were studied [31]. The enalapril
and valsartan group had better results with respect to
UF volume and D/P urea when compared to the
resting group. Surprisingly, these improvements were
not present in the enalapril–valsartan combination
group. Structural changes (peritoneal thickness and
number of vessels) were ameliorated in all treatment
groups compared to the resting group. In summary,
RAS blockade seemed more effective than peritoneal
resting with respect to ultraﬁltration volume, vascu-
larity and peritoneal thickness. Interestingly, dual
blockade with enalapril and valsartan had no addi-
tional beneﬁcial effects and even made some func-
tional improvements disappear.
Human data on the effect of RAS inhibition on the
peritoneal membrane are scarce. Kolesnyk and col-
leagues retrospectively analyzed data from 66 patients
treated with PD for at least 2 years, during which at
least 2 standard peritoneal permeability analyses
(SPA) were performed [32]. Thirty-six patients were
treated with an ACE inhibitor and/or ARB, 30 patients
did not receive any of these agents. In the ACE-
inhibitor/ARB group, small solute transport had
decreased, while it increased in the control group
during the time on PD. The same group from the
Netherlands studied data from 217 long-term PD
patients, of whom 120 were treated with an ACE
inhibitor/ARB, 87 were not and 10 who had them for
less than 25% of their time on PD [33]. The value of
the 24-h D/P creatinine was correlated with PD
duration (P = 0.01), but the slope of the rise of D/P
creatinine over time was less steep in the group treated
with RAS inhibition (P = 0.05). Increase in small
solute transport due to peritoneal inﬂammation and/or
ﬁbrosis is a well-known early sign of EPS. The
presented human data suggest that RAS inhibition
may play a role in preventing EPS in PD patients.
Wong et al. [34] showed that ACE activity is
independently associated with mortality in diabetic
PD patients. Apart from its role in macroangiopathy,
increased ACE activity might also be associated with
the development of EPS and hence explain its
association with mortality in PD patients. This is also
compatible with data from Fang et al. [35], showing
that treatment with ACE inhibitor and/or ARB in PD
patients was associated with a dramatically reduced
mortality independent of blood pressure and other
clinical and demographic variables.
Thalidomide
Thalidomide suppresses the production of tumor
necrosis factor (TNF) alpha by macrophages and
T cells, and based on its immunomodulatory, anti-
inﬂammatory and antiangiogenic effects, it may have
a role in the treatment of EPS [36].
Based on this rationale, Mondello and colleagues
induced EPS in 40 rats by intraperitoneal adminis-
tration of chlorhexidine, and thalidomide was given
orally [37]. Thalidomide reduced the extent and
severity of histological signs of peritoneal injury as
well as the degree of polymorphonuclear cell inﬁl-
tration in injured peritoneum. It also resulted in
reduction of the expression in the tissue of TNF-
alpha, TGF-beta, VEGF and NF-kappa B activation.
Everolimus
Everolimus is a macrolide immunosuppressive agent
that inhibits the activity of mammalian target of
rapamycin (mTOR), a cellular enzyme that plays a
key role in cell growth and proliferation. The
antiﬁbrotic effects of mTOR inhibitors are well
described [38–40].
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uremic EPS rat model [41]. Everolimus was more
effective than peritoneal rest with regard to vascu-
larity and peritoneal thickness. It had beneﬁcial
effects on UF failure, inﬂammation and ﬁbrosis.
Other experimental agents
More experimental data are available for the treatment
of EPS. However, none of these agents are currently
used in clinical practice to treat other diseases. This is
in contrast to the previously described agents. An
excellent review of all these experimental data for the
treatment of EPS was written by Park and colleagues
[6]. Agents such as pirfenidone (inhibits the expression
of TGF-beta 1 and TNF-alpha and scavenges reactive
oxygen species) [42], antiangiogenic strategies with
anti-VEGF neutralizing antibodies [43], TPN-470 [44]
and endostatin peptide [45] as well as oligonucleotides
against the collagen accumulating heat shock protein
47 (HSP-47) [46], ONO 487 (reduces the expression of
MMP-2, TGF-beta and VEGF and subsequent accu-
mulation of type I collagen) [47], chimeric DNA–RNA
hammerheadribozymetargetingTGF-betamRNA[48]
and hepatocyte growth factor [49] are discussed.
Stabilization of D/P creatinine over time on PD has
also been reported in a PD patient with metastatic renal
cellcarcinomatreatedwiththetyrosinekinaseinhibitor
sunitinib that also has anti-VEGF effects [50].
Biocompatible PD solutions
Numerous factors related to the composition of
standard peritoneal dialysis solutions possibly con-
tribute to the pathogenesis of peritoneal ﬁbrosis
during PD, including glucose, glucose-degradation
products [51], high osmolarity, low PH, lactate and
plasticizers released from the PD bags.
Garosi showed in a rabbit model that PD solutions
containing amino acids did not cause mesothelial
damage as opposed to solutions containing glucose
[52]. Submesothelial edema was worse in rabbits
dialyzed with glucose solution when compared to
amino acid solution, and within the glucose-contain-
ing dialysate group, the edema was worst in the
highest glucose group. No difference in submesothe-
lial inﬁltration was found between the groups.
The use of biocompatible solutions has been
advocated for in an attempt to prevent the
development of EPS [53]. However, to date, no
deﬁnitive human data are available to support the use
of biocompatible solutions for this purpose.
Recently, Yao and colleagues studied conventional
and biocompatible PD solutions in a rat model [54].
Twenty-eight rats were dialyzed three times daily for
4 weeks with a conventional or biocompatible solu-
tion each with various glucose concentrations. The
use of conventional solutions, especially the highest
glucose-containing ones, resulted in the expansion of
the submesothelial compact zone, loss of mesothelial
cell layer integrity, hypercellularity, accumulation of
collagen, increased vessel numbers and increased
TGF-beta1 expression, but this did not signiﬁcantly
change ﬂuid and solute peritoneal transport
characteristics.
VanWestrhenenetal.[55]investigatedinaratmodel
whether a ﬁlter-sterilized pyruvate-buffered dialysis
solution,madebycombinationoflowconcentrationsof
amino acids, glycerol and glucose (PYRAGG), would
inducelessperitonealabnormalitythanglucose/lactate-
based peritoneal solutions. No differences with respect
toperitonealtransportwerefoundbetweenthedifferent
groups. However, histological assessment of the peri-
toneum revealed that the PYRAGG group had lower
degree of ﬁbrosis and neoangiogenesis than the 2 other
groups. They concluded that a combination of osmotic
agents (each in lower concentration) rather than the use
of glucose alone (in high concentration) might help in
the prevention of neoangiogenesis and ﬁbrosis and
therefore EPS.
Whether the use of biocompatible solutions could
prevent the development of EPS is unclear as stated
before. Prolonged (longer than 3 years), large, ran-
domized trials are lacking to address this question. In
a recent editorial, Tejde et al. [56] reported on 2
patients who developed EPS even though they were
treated only with biocompatible solutions. However,
both patients had multiple episodes of PD peritonitis
possibly explaining why they developed EPS, even in
the presence of biocompatible solutions in the
peritoneal cavity.
Conclusions
Encapsulating peritoneal sclerosis (EPS) is a rare but
potentially dangerous complication in PD patients.
The exact pathogenesis is unfortunately not well
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matory and ﬁbrotic responses of the disease.
Some clinical experience in patients with EPS is
only available with tamoxifen and prednisone. How-
ever, partly due to the low number of patients with
EPS, there is a lack of large, randomized, controlled
trials. Awaiting further evidence and based on this
clinical experience, we support the use of tamoxifen
and prednisone for the treatment of EPS and also for
prophylaxis in the early inﬂammatory phase of EPS.
A daily dose of 20-mg tamoxifen seems to have only
minimal side effects. However, a dose up to 40 mg
per day may be required for prevention of EPS [10].
Follow-up for thrombotic complications and endo-
metrial cancer is essential.
The case reports on the effects of MMF and AZA
in patients with EPS are insufﬁcient to draw conclu-
sions that would inﬂuence daily clinical practice.
Recent animal data with rosiglitazone, N-acteyl-
cysteine, colchicine, RAS blockade, thalidomide and
everolimus are promising. However, in the absence of
further studies of these agents in patients with EPS,
we deem it difﬁcult to support their systematic use for
the treatment of EPS. On the other hand, treating
diabetic PD patients with rosiglitazone, trying to start
all PD patients with hypertension on an ACE
inhibitor and ﬁnally promoting the use of mTOR
inhibitors instead of CNI in PD patients who receive
a kidney transplant, do not seem to be unreasonable
suggestions.
Future directions
Future EPS research should not only focus on the
optimization of anti-inﬂammatory and antiﬁbrotic
treatment of EPS but also on the early detection of
the inﬂammatory EPS phase (Fig. 1). Because of the
non-speciﬁcity of the clinical syndrome that often
accompaniestheearlyphaseofEPS,biomarkersmight
be particularly useful. Serum markers such as CRP,
albumin and beta2-microglobulin [57] may be useful.
Efﬂuent markers such as CA-125, IL-6, VEGF [58],
TGF-beta, matrix metalloproteinase (MMP-2) [59],
ﬁbrin-degradation products (FDP) [60, 61], white cell
count with differentiation and hyaluronan levels [62]
have been shown in the past to be associated with
inﬂammation, tissue remodeling and peritoneal mem-
brane injury, and even increased solute transport.
Sampimon and colleagues analyzed the time course of
CA-125 and IL-6 preceding the diagnosis of EPS [63,
64]. They showed that an appearance rate of CA-125
lower than 33 U per minute and of IL-6 higher than
350 pg per minute in patients with ultraﬁltration
failure had a sensitivity of 70% and a speciﬁcity of
89% for the diagnosis of EPS. They suggest that
peritoneal samples should be taken regularly in PD
patients to detect early peritoneal membrane inﬂam-
mation. However, larger, randomized studies are
necessary to look further into the detection and
validation of these novel biomarkers for EPS.
In an attempt to facilitate the early diagnosis of
EPS, we suggest that the nephrology community
should aim at developing an EPS score. This EPS
score could potentially consist of a combination of
clinical, laboratory and radiological features
(Table 1). Ideally, this EPS score should be moni-
tored, for example, every 3–6 months and PD
patients should be started on prophylactic EPS
treatment with 20–40 mg of tamoxifen per day and
low-dose prednisone once the EPS score reaches a
speciﬁc threshold. Large, randomized trials are
obviously necessary to validate this strategy, and
these trials should be initiated once the nephrology
community agrees on the EPS score.
This proposed and hypothesized strategy of early
detection of EPS in the inﬂammatory phase by means
of an EPS score in combination with early treatment
of EPS offers an alternative to the idea of an ‘expiry
date’ for PD, which is propagated by some nephrol-
ogists as an attempt to try to prevent EPS from
developing. Opposed to the principle of discontinuing
PD according to pre-speciﬁed timing even before
EPS is suspected, we strongly believe that individual
evaluation of each PD patient based on clinical,
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Fig. 1 Proposed options for prevention (arrows 1-3) and
treatment (arrow 4) of encapsulating peritoneal sclerosis
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valid approach to patients on long-standing PD
treatment. Large, registry-based multicenter prospec-
tive studies are required to better understand and
delineate the genetic, demographic and treatment-
related risk factors contributing to the development of
EPS. Awaiting the results of these studies, measures
such as early use of tamoxifen, mTOR-inhibitor-
based immunosuppressive regimes in transplantation,
the use of biocompatible solutions and promoting the
use of RAS inhibition in PD patients, should be the
cornerstones in the prevention of the ﬁbrotic phase of
EPS rather than the systematic prescription of an
‘expiry date’ [65, 66].
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